1. A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2
   Ryota Tamura et al, 2019, Nature Communications CrossRef
2. Schwannomas of Brain and Spinal Cord
   Venelin Gerganov et al, 2023, Human Brain and Spinal Cord Tumors: From Bench to Bedside. Volume 2 CrossRef
3. Long-term outcomes of stereotactic radiosurgery for intracranial schwannoma in neurofibromatosis type 2: a genetic analysis perspective
   Yuki Shinya et al, 2024, Journal of Neuro-Oncology CrossRef
4. Biology and Genetics of Vestibular Schwannomas in Tumors of the Cerebellopontine Angle
   Dunia Abdul-Aziz et al, 2022, Surgery of the Cerebellopontine Angle CrossRef
5. Role of Bevacizumab as a prophylactic and rehabilitative treatment modality in cases of sporadic and syndromic vestibular schwannoma: Fifty shades of grey!
   Manjul Tripathi et al, 2020, Interdisciplinary Neurosurgery CrossRef
6. Rationale and Design of BeatNF2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Bevacizumab in Patients with Neurofibromatosis Type 2 Related Vestibular Schwannoma
   Masazumi Fujii et al, 2021, Current Oncology CrossRef
7. The heterogeneous subclones might be induced by cycling hypoxia which was aggravated along with the luminal A tumor growth
   Yue Kang et al, 2022, Tissue and Cell CrossRef
8. Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis
   Ryota Tamura, 2021, International Journal of Molecular Sciences CrossRef